About Nightstar
Nightstar is a company based in London (United Kingdom) founded in 2013 was acquired by Biogen in March 2019. Nightstar has raised $99.88 million across 3 funding rounds from investors including Biogen, Syncona and Imperial Innovations. The company has 15 employees as of December 31, 2021. Nightstar offers products and services including Alzheimer's Therapies, Multiple Sclerosis Medicines, and Spinal Muscular Atrophy Treatments. Nightstar operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter London, United Kingdom
- Employees 15 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nightstarx Limited
- Date of Incorporation 31 May, 2013
- Jurisdiction MAIDENHEAD, BERKSHIRE, ENGLAND
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nightstar
Nightstar offers a comprehensive portfolio of products and services, including Alzheimer's Therapies, Multiple Sclerosis Medicines, and Spinal Muscular Atrophy Treatments.
Treatments targeting neurological disorders like Alzheimer's.
Therapies for managing multiple sclerosis symptoms.
Medications for rare genetic disorders affecting muscles.
Funding Insights of Nightstar
Nightstar has successfully raised a total of $99.88M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $45 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nightstar
Nightstar has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Biogen, Syncona and Imperial Innovations.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are managed via private equity by Syncona.
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Investments in startups are focused on Europe and the US.
|
Locked | Locked | Locked |
Investor details for Nightstar
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nightstar
Investment portfolio details for Nightstar
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nightstar
Detailed financials for Nightstar
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nightstar Comparisons
Peer comparison for Nightstar
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nightstar
Nightstar operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Nightstar
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nightstar
Complete news archive for Nightstar
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nightstar
Nightstar was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Nightstar is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Dave Fellows is the current CEO of Nightstar.
Nightstar is a funded company, having raised a total of $99.88M across 3 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Nightstar is 15.
Nightstar was founded in 2013 in London, United Kingdom, within the biotechnology sector focused on gene therapy. Retinal disorders are addressed through candidates such as NSR-REP1, designated as an orphan drug by the FDA and EMA for choroideremia, NSR-RPGR in Phase 12 trials for X-linked retinitis pigmentosa, and NSR-BEST1 under preclinical evaluation for Best vitelliform macular dystrophy. Operations center on advancing these therapies for rare genetic conditions.
Nightstar's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Nightstar offers Alzheimer's Therapies, Multiple Sclerosis Medicines, and Spinal Muscular Atrophy Treatments.
Nightstar has 6 investors. Key investors include Biogen, Syncona, Imperial Innovations, Wellington, and NEA.